Free shipping on all orders over $ 500

PARP Poly-ADP-ribose polymerase

Cat.No.  Name Information
M1732 Talazoparib (BMN-673) Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.
M3932 NVP-TNKS656 NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM; > 300 fold selectivity against PARP1 and PARP2.
M4931 Rucaparib Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding affinity to eight other PARP domains.
M1664 AZD2281 (Olaparib) AZD 2281 (Olaparib, KU-0059436) is a potent PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. Olaparib is an autophagy and mitophagy activator.
M2215 Niraparib (MK-4827) MK-4827 (Niraparib) is a selective PARP1/2 inhibitor with an IC50 value of 3.8 nM/2.1 nM that increases the formation of PARP-DNA complexes through inhibition of PARPase activity, leading to DNA damage, apoptosis, PARP-1-dependent cell death (parthanatos) and cell death. Strong effector activity when acting on cancer cells harboring mutant BRCA-1 and BRCA-2. It is more than 330-fold more selective than PARP3, V-PARP and Tank1.
M1785 INO-1001 INO-1001 is a novel poly(ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 3 nM.
M13713 RK-287107 RK-287107 is a potent and specific tankyrase inhibitor with IC50s of 14.3 and 10.6 nM for tankyrase-1 and tankyrase-2, respectively. RK-287107 blocks colorectal cancer cell growth.
M2056 PJ34 hydrochloride PJ34 hydrochloride is the hydrochloride form of PJ34, a PARP inhibitor, and inhibits PARP-1-dependent cell death (parthanatos) with an EC50 of 20 nM, acting equally effectively on PARP1/2.
M2010 BSI-401 BSI-401 is a novel poly (ADP ribose) polymerase-1 inhibitor.
M1972 Iniparib Iniparib is an irreversible, noncompetitive inhibitor of PARP1 that disrupts binding between PARP1 and DNA by interacting with the DNA binding domain.
M1858 LT-674 LT-674 inhibits PARP-1 with an IC50 of 144 nM.
M1857 LT-628 LT-628 is the racemate of BMN 673 and LT-674.
M1645 AG14361 AG14361 is a novel poly (ADP-ribose) polymerase-1 inhibitor with a GI50 of 10.9 µM.
M1644 AG-014699 phosphate AG-014699 (PF-01367338, Rucaparib) is a PARP inhibitor with a Ki of 1.4 nM.
M1639 ABT-888 ABT-888 (Veliparib) is a potent inhibitor of PARP-1 and PARP-2 with Ki values of 5.2nM and 2.9nM respectively.
M54525 DSB-1522 DSB-1522 is a PARP1 inhibitor that can be used in tumor-related studies.
M54524 DM-5167 DM-5167 is a PARP1 inhibitor that can be used in studies related to triple negative breast cancer.
M54523 NMS-03305293 NMS-03305293 is a PARP inhibitor with high selectivity for PARP1 isoforms and low DNA capture effect, which specifically kills BRCA mutated tumor cells. In addition, NMS-03305293 can penetrate the blood-brain barrier and can be used in studies related to CNS tumors and brain metastatic tumors.
M49897 SNV1521 SNV1521 is a potential best-in-class (BIC), highly selective and CNS-permeable PARP1 inhibitor.
M45107 PARP/EZH2-IN-1 PARP/EZH2-IN-1 is a first-in-class dual PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.
M44714 3',4'-Dimethoxyflavone 3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris.
M43519 VEGFR/PARP-IN-1 VEGFR/PARP-IN-1 is a VEGFR/PARP dual inhibitor (IC50s: 191 nM and 60.9 nM respectively).
M41578 PARP-1-IN-4 PARP-1-IN-4 is a PARP-1 inhibitor.
M41577 PARP-1-IN-13 PARP-1-IN-13 is a PARP-1 inhibitor (IC50: 26 nM).
M41576 TNKS1/2-IN-2 TNKS1/2-IN-2 is a potent and selective tankyrases inhibitor.
M41575 PARP1-IN-14 PARP1-IN-14 is a potent PARP1 inhibitor, with an IC50 of 0.6 ± 0.1 nM.
M41574 YCH1899 YCH1899 is an orally active PARP inhibitor, with an IC50< 0.001 nM for PARP1/2.




Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.